Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.

B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf(V600E) kinase activity both in vitro and in vivo. Investigations into the structure-activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and pharmacokinetic profile. Compounds selectively inhibited B-Raf(V600E) in vitro and showed preferential antiproliferative activity in mutant B-Raf(V600E) cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-Raf(V600E) A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro.

[1]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Alastair J. King,et al.  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.

[3]  Joseph L. Kim,et al.  Conformation-specific effects of Raf kinase inhibitors. , 2012, Journal of medicinal chemistry.

[4]  Tyler T. Risom,et al.  The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase. , 2012, Bioorganic & medicinal chemistry letters.

[5]  T. Sim,et al.  Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics , 2012, Archives of pharmacal research.

[6]  Andrew G. Leach,et al.  Rationally designing safer anilines: the challenging case of 4-aminobiphenyls. , 2012, Journal of medicinal chemistry.

[7]  E. Laird,et al.  Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties. , 2012, Journal of medicinal chemistry.

[8]  E. Laird,et al.  Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties. , 2012, Bioorganic & medicinal chemistry letters.

[9]  C. Springer,et al.  Small molecule inhibitors of BRAF in clinical trials. , 2012, Bioorganic & medicinal chemistry letters.

[10]  K. Flaherty,et al.  BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.

[11]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[12]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[13]  R. Radinsky,et al.  Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth , 2010, Molecular Cancer Therapeutics.

[14]  M. Brown,et al.  Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .

[15]  M. Belvin,et al.  Abstract 5753: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010 .

[16]  Eric B Haura,et al.  A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[17]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[18]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[19]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[20]  David A. Scott,et al.  Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Jon Read,et al.  Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. , 2008, Bioorganic & medicinal chemistry letters.

[22]  Ultan McDermott,et al.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.

[23]  R. DeVita,et al.  The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine. , 2007, Bioorganic & medicinal chemistry letters.

[24]  Manfred Kansy,et al.  Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities , 2007, ChemMedChem.

[25]  P. Lyne,et al.  Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628 , 2007 .

[26]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[27]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[28]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[29]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[30]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[31]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[32]  B. Cathers,et al.  Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[33]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[34]  H. Tawbi,et al.  Raf kinase inhibitors for the treatment of melanoma , 2011, Drugs of the future.